{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:30:10Z","timestamp":1788388210017,"version":"build-2803163510"},"reference-count":22,"publisher":"Mattioli1885","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Psoriasis significantly impacts a patient\u2019s quality of life (QoL). Bimekizumab targets IL-17A and IL-17F, offering a broader blockade of the IL-17 pathway compared to other IL-17 inhibitors. Objectives: This study evaluated the clinical efficacy of bimekizumab in bio-naive and bio-experienced patients with moderate-to-severe psoriasis over a 52-week period, with a focus on improvements across different body areas and QoL. Methods: A retrospective analysis of real-world data was conducted on 132 patients from 8 medical centers. Efficacy was assessed using PASI scores, at baseline and at weeks 4, 16, 24, and 52, and DLQI scores. Patients were categorized based on prior biologic treatment experience. Results: The mean PASI score decreased for all patients, from 14.41 at baseline to 0.18 at week 52, indicating substantial improvement. Area-specific PASI subscores showed significant reductions: head (3.24 to 0.13), upper limb (8.49 to 0), trunk (8.35 to 0.03), and lower limb (8.61 to 0.12). Complete skin clearence was achieved by week 16 in the majority of patients: 85% achieved complete skin clearance in the head, 90% in upper limbs, and 94% in both trunk and lower limbs. DLQI scores significantly improved from 13.57 at baseline to 0.86 at week 16, highlighting the early positive impact of bimekizumab in improving QoL. When comparing PASI scores between bio-naive and bio-experienced patients, no significant difference was found. Conclusions: Bimekizumab demonstrates significant efficacy in reducing psoriasis severity across different body areas and improving QoL over a 52-week period. These findings support this robust treatment option for moderate-to-severe psoriasis.<\/jats:p>","DOI":"10.5826\/dpc.1502a4976","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T10:28:42Z","timestamp":1744367322000},"page":"4976","source":"Crossref","is-referenced-by-count":5,"title":["Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy"],"prefix":"10.5826","volume":"15","author":[{"given":"Annunziata","family":"Dattola","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Dermatology Unit \"Daniele Innocenzi\", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campione","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of \"Medicina dei Sistemi\", University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Amore","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Amato","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Caldarola","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Moretta","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Istituto Dermopatico dell\u2019Immacolata IRCCS Roma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Panasiti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pagnanelli","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Istituto Dermopatico dell\u2019Immacolata IRCCS Roma."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Roberti","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslana Gaeta","family":"Shumak","sequence":"additional","affiliation":[{"name":"ruslanagaetashumak@gmail.com"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \"Daniele Innocenzi\", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Tolino","sequence":"additional","affiliation":[{"name":"Dermatology Unit \"Daniele Innocenzi\", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tribuzi","sequence":"additional","affiliation":[{"name":"UOSD Ospedale Belcolle ASL Viterbo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Zanframundo","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Universit\u00e0 Campus Bio-Medico di Roma, Italy; Operative Research Unit of Dermatology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of \"Medicina dei Sistemi\", University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severino","family":"Persechino","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Mental Health and Sensory Organs, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Potenza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \"Daniele Innocenzi\", ASL Latina, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy, Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Richetta","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"10.5826\/dpc.1502a4976_ref1","doi-asserted-by":"crossref","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. The BMJ. 2020;369. doi:10.1136\/bmj.m1590","DOI":"10.1136\/bmj.m1590"},{"key":"10.5826\/dpc.1502a4976_ref2","doi-asserted-by":"crossref","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8. doi:10.3389\/fmed.2021.743180","DOI":"10.3389\/fmed.2021.743180"},{"key":"10.5826\/dpc.1502a4976_ref3","doi-asserted-by":"crossref","unstructured":"Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381-385. doi:10.1080\/14740338.2017.1288714","DOI":"10.1080\/14740338.2017.1288714"},{"key":"10.5826\/dpc.1502a4976_ref4","doi-asserted-by":"crossref","unstructured":"Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022;13. doi:10.3389\/fimmu.2022.880201","DOI":"10.3389\/fimmu.2022.880201"},{"key":"10.5826\/dpc.1502a4976_ref5","doi-asserted-by":"crossref","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9(AUG). doi:10.3389\/fimmu.2018.01682","DOI":"10.3389\/fimmu.2018.01682"},{"key":"10.5826\/dpc.1502a4976_ref6","doi-asserted-by":"crossref","unstructured":"Bunte K, Beikler T. Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci. 2019;20(14). doi:10.3390\/ijms20143394","DOI":"10.3390\/ijms20143394"},{"key":"10.5826\/dpc.1502a4976_ref7","doi-asserted-by":"crossref","unstructured":"Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study\u2014IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10. doi:10.3389\/fmed.2023.1243843","DOI":"10.3389\/fmed.2023.1196966"},{"key":"10.5826\/dpc.1502a4976_ref8","doi-asserted-by":"crossref","unstructured":"Warzyszak P, Ma\u0142ek R, Milczek M, et al. Psoriasis - a review of recent progress, characteristics, diagnostic management. Journal of Education, Health and Sport. 2022;13(2):149-155. doi:10.12775\/jehs.2023.13.02.021","DOI":"10.12775\/JEHS.2023.13.02.021"},{"key":"10.5826\/dpc.1502a4976_ref9","unstructured":"Bhatt TJ, Sanghavi UR, Zaveri ZH. Psoriasis: A Peer Review Article. www.ijfmr.com"},{"key":"10.5826\/dpc.1502a4976_ref10","doi-asserted-by":"crossref","unstructured":"Dasari S, Choudhary A, Madke B. Psoriasis: A Primer for General Physicians. Cureus. Published online April 24, 2023. doi:10.7759\/cureus.38037","DOI":"10.7759\/cureus.38037"},{"key":"10.5826\/dpc.1502a4976_ref11","doi-asserted-by":"crossref","unstructured":"Cami\u00f1a-Conforto G, Mateu-Arrom L, L\u00f3pez-Ferrer A, Puig L. Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient Prefer Adherence. 2023;17:1541-1549. doi:10.2147\/PPA.S350760","DOI":"10.2147\/PPA.S350760"},{"key":"10.5826\/dpc.1502a4976_ref12","doi-asserted-by":"crossref","unstructured":"Mahmoud AM. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients. Curr Med Res Opin. 2023;39(7):1031-1043. doi:10.1080\/03007995.2023.2228613","DOI":"10.1080\/03007995.2023.2228613"},{"key":"10.5826\/dpc.1502a4976_ref13","doi-asserted-by":"crossref","unstructured":"Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(5):355-362. doi:10.1080\/14740338.2023.2218086","DOI":"10.1080\/14740338.2023.2218086"},{"key":"10.5826\/dpc.1502a4976_ref14","doi-asserted-by":"crossref","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet. 2021;397(10273):475-486. doi:10.1016\/S0140-6736(21)00126-4","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"10.5826\/dpc.1502a4976_ref15","doi-asserted-by":"crossref","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. The Lancet. 2021;397(10273):487-498. doi:10.1016\/S0140-6736(21)00125-2","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"10.5826\/dpc.1502a4976_ref16","doi-asserted-by":"crossref","unstructured":"Hagino T, Saeki H, Fujimoto E, Kanda N. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: A single-center retrospective study. Journal of Dermatology. Published online May 1, 2024. doi:10.1111\/1346-8138.17186","DOI":"10.1111\/1346-8138.17186"},{"key":"10.5826\/dpc.1502a4976_ref17","doi-asserted-by":"crossref","unstructured":"Orsini D, Malagoli P, Balato A, et al. Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience-IL PSO (Italian Landscape Psoriasis). doi:10.5826\/dpc.1402a52","DOI":"10.5826\/dpc.1402a52"},{"key":"10.5826\/dpc.1502a4976_ref18","doi-asserted-by":"crossref","unstructured":"Merola JF, Gottlieb AB, Morita A, et al. AB1089 BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS. In: BMJ; 2023:1766-1767. doi:10.1136\/annrheumdis-2023-eular.3140","DOI":"10.1136\/annrheumdis-2023-eular.3140"},{"key":"10.5826\/dpc.1502a4976_ref19","unstructured":"Warren RB, Strober B, Lebwohl M, et al. Abstract Citation ID: Ljad113.366 PS14 Bimekizumab Response up to 3 Years in Patients with Moderate-to-Severe Plaque Psoriasis Who Responded at Week 16: Post Hoc Results from the BE BRIGHT Open-Label Extension Trial."},{"key":"10.5826\/dpc.1502a4976_ref20","doi-asserted-by":"crossref","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. British Journal of Dermatology. 2023;188(6):749-759. doi:10.1093\/bjd\/ljad035","DOI":"10.1093\/bjd\/ljad035"},{"key":"10.5826\/dpc.1502a4976_ref21","doi-asserted-by":"crossref","unstructured":"Natsis NE, Gottlieb AB. Bimekizumab for the treatment of psoriatic disease. Expert Opin Biol Ther. 2018;18(12):1193-1197. doi:10.1080\/14712598.2018.1538351","DOI":"10.1080\/14712598.2018.1538351"},{"key":"10.5826\/dpc.1502a4976_ref22","unstructured":"Sharma, P., Jadon, D. R., McGonagle, D., Ink, B., Assudani, D., Taieb, V., & Coates, L. C.. (n.d.). BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS WITH PRIOR INADEQUATE RESPONSE TO TNF INHIBITORS: IMPROVEMENTS OF PSARC OVER 16 WEEKS IN THE PHASE 3 BE COMPLETE TRIAL. P189. https:\/\/doi.org\/kead104.230"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4976\/3046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4976\/3496","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4976\/3045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:43:03Z","timestamp":1762522983000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/4976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1502a4976","relation":{"has-manifestation":[{"id-type":"other","id":"1-79-4976-g3045","asserted-by":"subject"},{"id-type":"other","id":"1-79-4976-g3046","asserted-by":"subject"},{"id-type":"other","id":"1-79-4976-g3496","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.v15i2","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"2"}}